Brian Buntz

Deloitte forecasts 25% of enterprises will use autonomous AI agents by 2025, reducing labor costs by 75% in some use cases.

A Google Cloud life sciences exec sees 2025 as the tipping point where GenAI projects begins to move more from pilots to profits.

In 2024, AI-focused startups continued to dominate the funding landscape with industry leaders like OpenAI ($6.6B), xAI ($6B), and Anthropic ($4B) leading the pack. Adding to this trend, MLflow and data lakehouse pioneer Databricks is raising what could be one of the largest venture rounds in history — a $9.5 billion raise plus $4.5 billion in debt financing, at a valuation exceeding $60 billion.

Explore how genetic validation, data-driven investments, and evolving clinical trials are transforming the biotech industry in 2025.

| As of December 5, 2024, the FDA had approved 44 new drugs, tracking close to the ten-year rolling average of 46 annual approvals . This pace, however, trails 2023's 55 approvals.

LinkedInEmailShare The architecture of progress extends beyond laboratories and research hubs. Here, in these 30 architectural monuments, you’ll find a unique blend of R&D centers alongside actual tributes to innovation, like the spiraling Mercedes-Benz Museum in Stuttgart, Germany. From the biotech brilliance Louis Kahn envisioned at the Salk Institute in 1959 to the plant-filled spheres of Amazon that debuted in 2018, such spaces embody humanity’s drive to reimagine the built environment.

| A growing chorus of experts agree: 2025 signals a year when AI and its generative variants (genAI) move beyond early experimentation into

German biotech leads in cell and gene therapy patents. U.S. universities hold robust portfolios.

| As 2024 drew to a close, the cell and gene therapy sector has witnessed a string of recent approvals and some positive clinical trial data

Long the stuff of sci-fi, humanoid robots are moving from prototypes toward practical use in factories and labs. AI is shifting from massive models toward smarter reasoning — and now Google is getting in the AI reasoning game while OpenAI is teasing the next iteration of its reasoning model. Meanwhile, biotech efforts like comprehensive epigenetic mapping and improved medical imaging AI are setting the stage for breakthroughs in healthcare.